Consequences of OKT3 administration via continuous infusion as compared to bolus infusion.
ten Berge
R J
RJ
Renal Transplant Unit, University of Amsterdam, The Netherlands.
Buysmann
S
S
van Diepen
F N
FN
Surachno
S
S
Hack
C E
CE
D000704:Analysis of Variance; D001777:Blood Coagulation; D001794:Blood Pressure; D001831:Body Temperature; D003167:Complement Activation; D016207:Cytokines / Q000097:blood; D005342:Fibrinolysis; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006098:Granulocytes / Q000502:physiology; D006339:Heart Rate; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D007262:Infusions, Intravenous; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D016853:Muromonab-CD3 / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*
D016207:Cytokines; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3